KDNY实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (11 Aug 2023 @ 04:00):

Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases...

Stats
今日成交量	3.28M
平均成交量	2.04M
市值	2.71B
EPS	$0 ( 2024-02-26 )
下一个收益日期	( $0 ) 2024-05-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-12.47
ATR14	$0.453 (1.12%)

Insider Trading

Date	Person	Action	Amount	type
2023-08-11	Thomas Dolca	Sell	13 300	Common Stock
2023-08-11	Thomas Dolca	Sell	23 522	Stock Option (Right to Buy)
2023-08-11	Thomas Dolca	Sell	5 948	Stock Option (Right to Buy)
2023-08-11	Thomas Dolca	Sell	13 300	Stock Option (Right to Buy)
2023-08-11	Oxtoby Andrew	Sell	160 000	Stock Option (Right to Buy)

INSIDER POWER
-96.03
Last 99 transactions
Buy: 289 232 \| Sell: 10 194 260

音量相关性

長: 0.28 (neutral)

短: 0.00 (neutral)

Signal:(78.495) Neutral

Aduro Biotech Inc 相关性

10 最正相关
KIN	0.983
SCPL	0.975
ABST	0.973
BWC	0.972
CDRO	0.971
NXGN	0.971
TXRH	0.962
IMGN	0.961
SRRA	0.961
ISEE	0.956

10 最负相关
CYAN	-0.967
PEAR	-0.96
SSP	-0.958
AUPH	-0.958
PYR	-0.957
SABR	-0.955
QDEL	-0.954
PENN	-0.953
PTE	-0.952
BRQS	-0.952

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Aduro Biotech Inc 相关性 - 货币/商品

0.39
( neutral )

0.81
( strong )

0.01
( neutral )

0.24
( neutral )

0.61
( weak )

-0.79
( moderate negative )

Aduro Biotech Inc 财务报表

Annual	2022
营收:	$6.13M
毛利润:	$4.41M (71.90 %)
EPS:	$-2.87

FY	2022
营收:	$6.13M
毛利润:	$4.41M (71.90 %)
EPS:	$-2.87

FY	2021
营收:	$51 625.00
毛利润:	$0.00 (0.00 %)
EPS:	$-0.00226

FY	2020
营收:	$827 000
毛利润:	$827 000 (100.00 %)
EPS:	$-6.20

Financial Reports:

No articles found.

Aduro Biotech Inc

Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington.

实时更新： Aduro Biotech Inc [KDNY]

Upcoming Earnings Alert